Metabolic

AOD9604

AOD9604 is a modified peptide derived from the C-terminal region of human growth hormone. Research on this fragment is not interchangeable with research on full-length growth hormone.

Reviewed September 2026

Residues
16. verified: 16 main-chain residues in the published reference structure; disulfide changes mass and ionization, not residue count.
Average mass
1,815.1 Da. verified: Reference form: AOD9604 reference cyclic-disulfide peptide YLRIVQCRSVEGSCGF (Cys7–Cys14), free termini; not its reduced dithiol form.; formula C78H123N23O23S2. PubChem average molecular weight, not monoisotopic mass. Excludes unlisted counterions, solvent and formulation ingredients; not a sold-lot measurement.
pI
Not established. unverified: No documented pI or validated full modification-aware ionization model was established for this exact reference form. Terminal chemistry, noncanonical residues, lipidation, cyclization or non-alpha linkages cannot be silently omitted. Not formulation pH.

Reference details

Reference details
Residues16
Average mass1,815.1 Da
pINot established
Identity
Research areaMetabolic

Property basis and sources

These describe the reference compound or formulation, not identification or testing of the supplied lot.

AOD9604 reference cyclic-disulfide peptide YLRIVQCRSVEGSCGF (Cys7–Cys14), free termini; not its reduced dithiol form. Reference only, not a sold-lot measurement.

  • Residues: 16 (verified). 16 main-chain residues in the published reference structure; disulfide changes mass and ionization, not residue count. Residues source 1 Residues source 2
  • Average mass: 1,815.1 Da (verified). Reference form: AOD9604 reference cyclic-disulfide peptide YLRIVQCRSVEGSCGF (Cys7–Cys14), free termini; not its reduced dithiol form.; formula C78H123N23O23S2. PubChem average molecular weight, not monoisotopic mass. Excludes unlisted counterions, solvent and formulation ingredients; not a sold-lot measurement. Average mass source 1
  • pI: Not established (unverified). No documented pI or validated full modification-aware ionization model was established for this exact reference form. Terminal chemistry, noncanonical residues, lipidation, cyclization or non-alpha linkages cannot be silently omitted. Not formulation pH. pI source 1

Reference scope and linked records

Reference type: Modified peptide.

This is a research-reference entry, not a product certificate, treatment recommendation or administration guide. The sources below describe their own materials and methods. Catalogue identity, lot testing and clinical evidence are separate questions.

Catalogue context: AOD9604. The product retains its own name and specification; this link does not certify equivalence to published study material.

Related references

Sources and their scope

  1. Human GH and AOD9604: lipid metabolism in obese and beta3-AR knockout mice. Source for the chemistry or study context discussed above; not an Aminos lot certificate.

Source check: 26 September 2026. This is an editorial source check, not a claim of independent clinical or laboratory review.

About AOD9604

Identity and context

The selected study compares human growth hormone and AOD9604 in lipid-metabolism experiments. Sharing an origin within the hormone does not make the fragment a replacement for the complete molecule or establish all of its biological actions.

Reference classification

Modified peptide. The linked catalogue product is AOD9604. This reference does not independently authenticate the material supplied.

Storage and handling

Analytical specification

Obtain the complete fragment structure, terminal chemistry and disulfide specification. Do not insert the sequence of full growth hormone into a calculator as a substitute for the actual analogue.

Storage and experimental handling

Use the documented conditions for the actual chemical form and preparation. No universal storage temperature, expiry or solution shelf life is assigned here. Follow the lot documentation, safety data sheet and validated laboratory protocol; this page is not a reconstitution or administration guide.

Research evidence

Research evidence for this compound
AreaSummaryEvidence
What the source examinesThe investigators studied obese mice and beta3-adrenoceptor knockout mice. The results differed between chronic treatment and an acute experiment, and the authors concluded that the observed lipolytic actions were not mediated directly through the beta3 receptor. That complexity matters when discussing mechanism.Source context
What cannot be inferredA mouse lipid-metabolism result is not a demonstrated human weight-loss outcome. The paper does not test Aminos material and cannot establish a clinical use, manufacturing standard or lot identity for it.Evidence limits

References

Sources used for the data on this page, checked September 2026.

  1. Human GH and AOD9604: lipid metabolism in obese and beta3-AR knockout micePrimary source for the reference discussion; not lot-specific product evidence.

Reference information only. This page describes the chemistry and published research context of a laboratory compound. Nothing here is medical or dosing advice. Aminos compounds are for laboratory research use only and are not medicines.